Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy

References

• Moehler M, Blechacz B, Weiskopf N, Zeidler M, Stremmel W, Rommelaere J, Galle PR, Cornelis JJ. Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Ther 2001; 8:158-67; PMID:11332986; http://dx.doi.org/10.1038/sj.cgt.7700288
   PubMed Web of Science ®Google Scholar
• Donnelly O, Harrington K, Melcher A, Pandha, H. Live viruses to treat cancer. J R Soc Med 2013; 106:310-4; PMID:23824333; http://dx.doi.org/10.1177/0141076813494196
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658-70; PMID:22781695; http://dx.doi.org/10.1038/nbt.2287
   PubMed Web of Science ®Google Scholar
• Atherton MJ, Lichty BD. Evolution of oncolytic viruses: novel strategies for cancer treatment. Immunotherapy 2013; 5:1191-206; PMID:24188674; http://dx.doi.org/10.2217/imt.13.123
   PubMed Web of Science ®Google Scholar
• Carpenter SG, Carson J, Fong Y. Regional liver therapy using oncolytic virus to target hepatic colorectal metastases. Semin Oncol 2010; 37:160-69; PMID:20494708; http://dx.doi.org/10.1053/j.seminoncol.2010.03.001
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Collichio FA, Amatruda T, Senzer NN, Chesney J, Delman KA, Spitler LE, Puzanov I, Doleman S, Ye Y et al.. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol (Meeting Abstracts) 31, LBA9008- (2013).
   Google Scholar
• Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999; 10:385-93; PMID:10048391; http://dx.doi.org/10.1089/10430349950018832
   PubMed Web of Science ®Google Scholar
• Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 2013; 12:103; PMID:24020520; http://dx.doi.org/10.1186/1476-4598-12-103
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Sur Oncol 2010; 17:718-30; PMID:19915919; http://dx.doi.org/10.1245/s10434-009-0809-6
   PubMed Web of Science ®Google Scholar
• Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res 2016; 22:1048-54; PMID:26719429; http://dx.doi.org/10.1158/1078-0432.CCR-15-2667
   PubMed Web of Science ®Google Scholar
• Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther 2000; 2:324-9; PMID:11020347; http://dx.doi.org/10.1006/mthe.2000.0130
   PubMed Web of Science ®Google Scholar
• Wang X, Yu W, Li H, Yu J, Zhang X, Ren X, Cao S. Can the dual-functional capability of CIK cells be used to improve antitumor effects? Cell Immunol 2014; 287:18-22; PMID:24355711; http://dx.doi.org/10.1016/j.cellimm.2013.11.009
   PubMed Web of Science ®Google Scholar
• Wang QJ, Wang H, Pan K, Li YQ, Huang LX, Chen SP, He J, Ke ML, Zhao JJ, Li JJ et al. Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer 2010; 29:641-8; PMID:20591215; http://dx.doi.org/10.5732/cjc.009.10772
   PubMedGoogle Scholar
• Zhong R, Han B, Zhong H. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol 2014; 35:987-94; PMID:24006222; http://dx.doi.org/10.1007/s13277-013-1132-1
   PubMed Web of Science ®Google Scholar
• Holt GE, Podack ER, Raez LE. Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy 2011; 8:43-54; PMID:21359153
   PubMedGoogle Scholar
• Kakimi K, Nakajima J, Wada H. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer 2009; 65:1-8; PMID:19062127; http://dx.doi.org/10.1016/j.lungcan.2008.10.018
   PubMed Web of Science ®Google Scholar
• Jakel CE, Schmidt-Wolf IG. An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. Expert Opin Biol Ther 2014; 14:905-16; PMID:24673175; http://dx.doi.org/10.1517/14712598.2014.900537
   PubMed Web of Science ®Google Scholar
• Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009; 27:130-9; PMID:19294626; http://dx.doi.org/10.1002/hon.886
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang Z, Tang L, Xu YC, Xie ZM, Gu XF, Wang HX. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 2012; 14:483-93; PMID:22277010; http://dx.doi.org/10.3109/14653249.2011.649185
   PubMed Web of Science ®Google Scholar
• Tao L, Huang G, Shi S, Chen L. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models. Med Oncol 2014; 31:777; PMID:24271420; http://dx.doi.org/10.1007/s12032-013-0777-3
   PubMed Web of Science ®Google Scholar
• Gold JE, Ross SD, Krellenstein DJ, LaRosa F, Malamud SC, Osband ME. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients. Eur J Cancer 1995; 31a: 698-708; PMID:7640041; http://dx.doi.org/10.1016/0959-8049(94)00523-8
   PubMed Web of Science ®Google Scholar
• Wongkajornsilp A, Wamanuttajinda V, Kasetsinsombat K, Duangsa-ard S, Sa-ngiamsuntorn K, Hongeng S, Maneechotesuwan K. Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3(+)CD56(+) subset through the co-culturing dendritic cells. PLoS One 2013; 8:e78980; PMID:24232460; http://dx.doi.org/10.1371/journal.pone.0078980
   PubMedGoogle Scholar
• Huang X, Chen YT, Song HZ, Huang GC, Chen LB. Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World J Gastroenterol 2011; 17:3002-11; PMID:21799646; http://dx.doi.org/10.3748/wjg.v17.i25.3002
   PubMed Web of Science ®Google Scholar
• Rao B, Han M, Wang L, Gao X, Huang J, Huang M, Liu H, Wang J. Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J Transl Med 2011; 9:17; PMID:21272332; http://dx.doi.org/10.1186/1479-5876-9-17
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X, Ren X. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 2012; 18:1751-9; PMID:22275504; http://dx.doi.org/10.1158/1078-0432.CCR-11-2442
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, Harrington K, Nemunaitis J, Zloza A, Wolf M et al. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer 2016; 4:12; PMID:26981242; http://dx.doi.org/10.1186/s40425-016-0116-2
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-71; PMID:25428505; http://dx.doi.org/10.1038/nature13954
   PubMed Web of Science ®Google Scholar
• Song G, Wang X, Jia J, Yuan Y, Wan F, Zhou X, Yang H, Ren J, Gu J, Lyerly HK. Elevated level of peripheral CD8(+)CD28(−) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. Cancer Immunol Immunother 2013; 62:1123-30; PMID:23604172; http://dx.doi.org/10.1007/s00262-013-1424-8
   PubMed Web of Science ®Google Scholar
• Song QK, Ren J, Zhou XN, Wang XL, Song GH, Di LJ, Yu J, Hobeika A, Morse MA, Yuan YH et al. The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion. Oncotarget 2015; 6:41350-9; PMID:26462021; https://dx.doi.org/10.18632/oncotarget.5534
   PubMed Web of Science ®Google Scholar
• Wang J, Wang W, Li R, Li Y, Tian G, Goodman L, Fan W, Zhang J, Li J, Zhang J et al. The diploid genome sequence of an Asian individual. Nature 2008; 456:60-5; PMID:18987735; http://dx.doi.org/10.1038/nature07484
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ. Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015; 14:642-662; PMID:26323545; http://dx.doi.org/10.1038/nrd466
   Google Scholar